Mounjaro (tirzepatide) works by activating two gut hormone receptors at the same time, triggering a cascade of effects that lower blood sugar, slow digestion, and reduce appetite. It’s the first drug in its class to target both of these pathways simultaneously, which is a key reason it produces larger improvements in blood sugar control and weight loss than older medications that only target one.
The Dual Hormone System
Your gut naturally produces two hormones after you eat: GLP-1 and GIP. Both signal your pancreas to release insulin, but they also influence appetite, digestion speed, and how your body stores fat. Most older injectable diabetes and weight loss medications mimic only GLP-1. Mounjaro mimics both.
The drug’s molecular structure is built on the GIP hormone backbone, with modifications that let it also activate GLP-1 receptors. At the GIP receptor, tirzepatide binds with roughly the same strength as the natural hormone. At the GLP-1 receptor, it behaves differently: it strongly triggers insulin-related signaling but is less likely to cause the receptor to shut down and stop responding. In pharmacology terms, it’s “biased” toward the productive signaling pathway and away from the desensitization pathway. This may help explain why the drug’s effects remain robust over time rather than fading as the body adapts.
How It Lowers Blood Sugar
Mounjaro increases insulin secretion and reduces glucagon release, but only when blood sugar is elevated. This glucose-dependent mechanism is important because it means the drug doesn’t push blood sugar dangerously low during fasting or between meals the way some older diabetes medications can. When you eat and glucose rises, the drug amplifies your pancreas’s natural insulin response. At the same time, it suppresses glucagon, a hormone that tells your liver to release stored sugar into the bloodstream.
The result is lower blood sugar both after meals and during fasting. In the SURPASS-2 clinical trial, participants with type 2 diabetes saw their HbA1c (a measure of average blood sugar over roughly three months) drop by about 2.0 percentage points on the 5 mg dose, 2.2 points on 10 mg, and 2.3 points on 15 mg. For context, many people with type 2 diabetes start treatment with an HbA1c around 8% or higher, and the general target is below 7%. A two-point reduction can move someone from poorly controlled diabetes to near-normal levels.
How It Reduces Appetite and Weight
Mounjaro slows gastric emptying, meaning food stays in your stomach longer after a meal. This prolongs the physical sensation of fullness, which naturally reduces how much you eat at the next meal or snack. The effect on stomach emptying is strongest after the first dose and becomes less pronounced over time, though appetite suppression tends to persist through other mechanisms, including direct effects on hunger signaling in the brain.
The weight loss results from clinical trials have been striking. In the SURMOUNT-1 trial, which enrolled adults with obesity or overweight (without diabetes), participants lost an average of 15.0% of their body weight on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg over 72 weeks. For someone weighing 250 pounds, that highest dose translates to roughly 52 pounds lost over a year and a half. These numbers exceeded what had been seen with GLP-1-only medications, suggesting the addition of GIP receptor activation contributes meaningfully to weight reduction.
How It’s Taken
Mounjaro is a once-weekly injection given under the skin of the abdomen, thigh, or upper arm. You start at 2.5 mg, which is a ramp-up dose designed to let your body adjust rather than to control blood sugar. After four weeks, the dose increases to 5 mg. From there, your prescriber can raise the dose in 2.5 mg steps every four weeks or longer, up to a maximum of 15 mg, depending on how you respond and what you can tolerate.
The drug has a half-life of about five days, meaning it clears your system slowly. Steady-state levels, where the amount entering and leaving your body each week is balanced, are reached after about four weeks of consistent dosing. This long half-life is what makes weekly dosing possible and also means that side effects, if they occur, can take several days to subside.
Common Side Effects
Gastrointestinal symptoms are the most frequent side effects, and they’re a direct consequence of the drug’s mechanism. Slowing digestion and altering gut hormone signaling can cause nausea, diarrhea, and vomiting, especially during the early weeks and after dose increases.
In a meta-analysis of clinical trial data, about 20% of people taking tirzepatide experienced nausea compared to 10% on placebo. Diarrhea affected roughly 16% versus 9% on placebo, and vomiting occurred in about 9% versus 5%. These symptoms are typically mild to moderate and tend to improve as the body adjusts. The gradual dose escalation schedule exists specifically to minimize these effects. Eating smaller meals, avoiding high-fat foods, and staying hydrated can also help.
Who Should Not Take It
Mounjaro carries an FDA boxed warning related to thyroid cancer. In animal studies, drugs in this class caused thyroid tumors, though it’s unknown whether the same risk applies to humans. The drug is contraindicated if you or a close family member has a history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated if you’ve had a serious allergic reaction to tirzepatide or any of the drug’s inactive ingredients, as cases of anaphylaxis and severe swelling have been reported.
Why Dual Agonism Matters
The practical difference between Mounjaro and GLP-1-only drugs comes down to the addition of GIP receptor activation. GIP plays a role in how your body processes fat and responds to nutrients that GLP-1 doesn’t fully cover. By engaging both receptors, Mounjaro appears to produce greater insulin sensitivity, larger reductions in blood sugar, and more significant weight loss than targeting GLP-1 alone. The biased signaling at the GLP-1 receptor, where the drug triggers the beneficial pathway without shutting the receptor down as quickly, may also mean its effects hold up better over months and years of use compared to drugs that cause more receptor fatigue.